Antibe Therapeutics Inc., a commercial-stage health care company focused on pain, inflammation and regenerative medicine, is pleased to announce the signing of an exclusive Licencing and Distribution Agreement with Induce Biologics Inc. (“Induce”) for the Canadian rights for Induce’s URIST™ biological product for dental and craniofacial applications.
URIST™ is a novel bone graft substitute that contains bone morphogenetic protein-2 (BMP), and is being developed as a means of promoting the regeneration of bone following dental and oral maxillofacial surgery. Animal studies have demonstrated the ability of URIST™ to potently stimulate bone re-growth. Orthobiologics (the use of biological approaches to regenerate and repair bone) is estimated to be a US$4.4 billion market. BMP-based products are among the largest segments of this market.
“This is the first product that we have in-licenced since the completion of our transformational acquisition of Citagenix, and is consistent with our strategy of building a portfolio of innovative technologies in the exciting field of tissue regeneration,” said Daniel Legault, President and CEO of Antibe. “URIST™ is a pre-approval, high-return opportunity that has the potential to disrupt the present landscape of commercial bone regeneration products. In addition to URIST™, we hope to secure additional licencing opportunities in the coming months to further increase shareholder value.” Under the terms of the agreement, Induce will receive an upfront payment of CDN$250,000.
Citagenix Inc. (“Citagenix”), a wholly owned subsidiary of Antibe, is a leader in the sales and marketing of commercial tissue regeneration products across Canada and has over 15 distribution partners globally. Antibe is actively pursuing both pre-approval and commercial business development opportunities that directly leverage Citagenix’s distribution resources and respected, knowledgeable sales force.
Induce Biologics Inc. / URIST™
Induce is a private biotechnology company with a focus on the advancement of its URIST™ bone putty technology. URIST™ comes in a convenient kit that provides a multi-phasic release of the active ingredient (BMP) at the surgical site. The final pre-clinical work required to advance URIST™ into clinical development is currently underway and the processes required to manufacture the BMP and URIST™ have been developed.
Antibe Therapeutics Inc. develops safer medicines for pain and inflammation. Antibe’s technology involves linking a hydrogen sulphide-releasing molecule to an existing drug to produce a patented, improved medicine. Antibe’s lead drug ATB-346 targets the global need for a safer non-steroidal anti-inflammatory drug (NSAID) for chronic pain and inflammation. ATB-352, the second drug in Antibe’s pipeline, targets the urgent global need for a safer analgesic for treating severe acute pain, while ATB-340 is a GI-safe derivative of aspirin.
